Abstract
BackgroundThe majority of colorectal carcinomas (CRCs) are insensitive to programmed death protein-1/programmed death-ligand 1 (anti-PD-1/PD-L1) immune checkpoint inhibitor (ICI) antibodies. While there are many causes for ICI insensitivity, recent studies...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have